Market Cap 44.74B
Revenue (ttm) 30.24B
Net Income (ttm) 712.32M
EPS (ttm) N/A
PE Ratio 9.18
Forward PE 8.32
Profit Margin 2.36%
Debt to Equity Ratio 0.66
Volume 1,467,500
Avg Vol 2,786,960
Day's Range N/A - N/A
Shares Out 3.18B
Stochastic %K 68%
Beta 0.21
Analysts Sell
Price Target $18.10

Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate,...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 81 3 3278-2111
Fax: 81 3 3278-2000
Address:
1-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan
outlawinvestor1
outlawinvestor1 Oct. 24 at 3:15 AM
$RZLT i was thinking through who may be the most likely acquirer. my guess based on recent bod and mgmt team additions is that it's $RARE. sunil karnawat joined in august 2025 as cco. prior to this, he was an exec at ultragenyx from 2017-2024. erik harris joined the bod in march 2025 and currently serves as cco of ultragenyx. the question i have is how they would structure this deal. ultragenyx doesn't have a lot of cash, but quite a bit of debt. thus, they likely wouldn't be able to do an all-cash deal funded with additional debt. so it would need to likely be cash + stock + contingent payments. i would much rather it be $LLY $NVO $TAK but signs don't point to any of these companies.
1 · Reply
DaBullRunMasta
DaBullRunMasta Oct. 23 at 5:23 PM
$BBAI $TAK $ITGR $FRMI $VIVK All money makers and bootie shakers!!
0 · Reply
DaBullRunMasta
DaBullRunMasta Oct. 23 at 5:15 PM
$TAK $DNLI Keep an keen eye on! Market shake and bakers baby!
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 22 at 6:32 PM
$TAK Share Price: $14.11 Contract Selected: Apr 17, 2026 $15 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.65 – $0.79 Potential Upside: 60% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
DaBullRunMasta
DaBullRunMasta Oct. 22 at 6:09 PM
$TAK I'm in let's ride!!! Took my profits from $EONR
1 · Reply
Everlast1286
Everlast1286 Oct. 22 at 6:44 AM
$TAK just released 230am 10/22 we have another runner for 4am get ready boys $RANI $BYND $NVTS
0 · Reply
Quantumup
Quantumup Oct. 17 at 7:30 PM
Citi⬆️ $PTGX's PT to $96 from $72 and kept it at a Buy rating after updating its model and said Rusfertide's De-Risked Profile Supports Upside $JNJ $TAK $BMY $ABVX Citi additionally said:
0 · Reply
GODOFUSD
GODOFUSD Oct. 17 at 3:10 PM
$BMEA $TAK Someone on X quoted this : On Sept 25, Takeda filed a Form 6-K reversing ¥834 B (~$5.6 B) of long-locked reserves back into retained earnings. Not cash raised — but cash unlocked. That’s how you prep for something big: buybacks, dividends… or strategic M&A. Coincidences ? https://fintel.io/doc/sec-takeda-pharmaceutical-co-ltd-1395064-6k-2025-september-25-20356-8030
1 · Reply
GODOFUSD
GODOFUSD Oct. 17 at 2:48 PM
$BMEA Apparently there are internal discussions about BMEA at $TAK Source: linkedin https://linkedin.com/company/biomeafusion Go check last post about 52W data results. An employee of TAKEDA ask some more info. There Novartis story is a BS without any sources or proof Partnership ? buyout ? Privat investment ?
3 · Reply
GODOFUSD
GODOFUSD Oct. 16 at 1:11 PM
$BMEA there are internal discussions about BMEA at $TAK proof: lindedin go check last post about 52W data results Partnership ? buyout ?
0 · Reply
Latest News on TAK
Takeda Pharmaceutical to exit cell therapy research

Oct 1, 2025, 9:41 AM EDT - 23 days ago

Takeda Pharmaceutical to exit cell therapy research


Shares of Asian drugmakers drop after Trump threatens tariffs

Sep 25, 2025, 10:52 PM EDT - 4 weeks ago

Shares of Asian drugmakers drop after Trump threatens tariffs


What's Going On With Takeda Stock On Friday?

Aug 22, 2025, 11:21 AM EDT - 2 months ago

What's Going On With Takeda Stock On Friday?


Takeda Announces New Assignments of Directors

Jun 25, 2025, 3:07 AM EDT - 4 months ago

Takeda Announces New Assignments of Directors


outlawinvestor1
outlawinvestor1 Oct. 24 at 3:15 AM
$RZLT i was thinking through who may be the most likely acquirer. my guess based on recent bod and mgmt team additions is that it's $RARE. sunil karnawat joined in august 2025 as cco. prior to this, he was an exec at ultragenyx from 2017-2024. erik harris joined the bod in march 2025 and currently serves as cco of ultragenyx. the question i have is how they would structure this deal. ultragenyx doesn't have a lot of cash, but quite a bit of debt. thus, they likely wouldn't be able to do an all-cash deal funded with additional debt. so it would need to likely be cash + stock + contingent payments. i would much rather it be $LLY $NVO $TAK but signs don't point to any of these companies.
1 · Reply
DaBullRunMasta
DaBullRunMasta Oct. 23 at 5:23 PM
$BBAI $TAK $ITGR $FRMI $VIVK All money makers and bootie shakers!!
0 · Reply
DaBullRunMasta
DaBullRunMasta Oct. 23 at 5:15 PM
$TAK $DNLI Keep an keen eye on! Market shake and bakers baby!
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 22 at 6:32 PM
$TAK Share Price: $14.11 Contract Selected: Apr 17, 2026 $15 Calls Buy Zone: $0.38 – $0.47 Target Zone: $0.65 – $0.79 Potential Upside: 60% ROI Time to Expiration: 176 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
DaBullRunMasta
DaBullRunMasta Oct. 22 at 6:09 PM
$TAK I'm in let's ride!!! Took my profits from $EONR
1 · Reply
Everlast1286
Everlast1286 Oct. 22 at 6:44 AM
$TAK just released 230am 10/22 we have another runner for 4am get ready boys $RANI $BYND $NVTS
0 · Reply
Quantumup
Quantumup Oct. 17 at 7:30 PM
Citi⬆️ $PTGX's PT to $96 from $72 and kept it at a Buy rating after updating its model and said Rusfertide's De-Risked Profile Supports Upside $JNJ $TAK $BMY $ABVX Citi additionally said:
0 · Reply
GODOFUSD
GODOFUSD Oct. 17 at 3:10 PM
$BMEA $TAK Someone on X quoted this : On Sept 25, Takeda filed a Form 6-K reversing ¥834 B (~$5.6 B) of long-locked reserves back into retained earnings. Not cash raised — but cash unlocked. That’s how you prep for something big: buybacks, dividends… or strategic M&A. Coincidences ? https://fintel.io/doc/sec-takeda-pharmaceutical-co-ltd-1395064-6k-2025-september-25-20356-8030
1 · Reply
GODOFUSD
GODOFUSD Oct. 17 at 2:48 PM
$BMEA Apparently there are internal discussions about BMEA at $TAK Source: linkedin https://linkedin.com/company/biomeafusion Go check last post about 52W data results. An employee of TAKEDA ask some more info. There Novartis story is a BS without any sources or proof Partnership ? buyout ? Privat investment ?
3 · Reply
GODOFUSD
GODOFUSD Oct. 16 at 1:11 PM
$BMEA there are internal discussions about BMEA at $TAK proof: lindedin go check last post about 52W data results Partnership ? buyout ?
0 · Reply
Quantumup
Quantumup Oct. 15 at 11:16 AM
UBS⬇️ $HRMY's PT to $43 from $50/⬇️'29 sales ests to $1.08B from $1.34B on Wakix competitive pressures in the NT1/NT2 mkt from pot'l orexin agonists launch. $TAK $ALKS $CNTA ESALY NLSP JAZZ AXSM AVDL UBS said in its note to investors: Based on our buy-side conversations, investors are concerned as HRMY's opportunity to grow into a multi-asset company dwindled with the recent Zygel Ph3 FXS failure (and IH approval rejection). Moreover, it is likely that HRMY's base business Wakix will face competitive pressure in the narcolepsy market with potential orexin agonists launch. We lower our PT to $43 (from $50) based on an unchanged 2.75x multiple on lower 2029E sales of $1.08BN (from $1.34BN) due to the potential competition on Wakix sales and zeroed out Zygel sales. Our PT is supported by DCF.
0 · Reply
Quantumup
Quantumup Oct. 8 at 11:59 AM
Mizuho reiterated $ALKS Outperform/$40 $CNTA $AXSM $TAK Mizuho said in its note: We preview 3Q25 for ALKS and expect slightly above-consensus 3Q25 revenues of $358M (vs. $355M Bloomberg cons) and GAAP EPS of $0.31 (vs. $0.30 cons), driven by potentially above-consensus Aristada and Lybalvi sales. That said, we believe investors are likely more focused on the Vibance-2 Phase 2 readout for alixorexton (ALKS-2680) in narcolepsy type 2 (NT2) this fall. Heading into this readout, we believe the key concerns are potential for high visual AE rates as Vibrance-2 evaluates higher doses (10, 14, 18mg) than 8mg, which demonstrated a significantly higher-than-expected visual AE rate of 29% in the Vibrance-1 NT1 trial. These concerns may be overstated, as NT2/IH patients are likely less hypersensitive to orexin than NT1, and so the visual AE rates may not be as high. Thus, the risk/reward could be skewed to the upside. Maintain $40 PT and OP rating.
0 · Reply
Jtlo
Jtlo Oct. 1 at 10:11 PM
$TAK buy $OVID already
1 · Reply
Quantumup
Quantumup Oct. 1 at 3:16 PM
Wells Fargo added $ALKS (Overweight) and $CNTA (Overweight) onto its 4Q25 Tactical Ideas List. $AXSM $TAK Wells Fargo said that it sees upside to CNTA shares if ALKS' alixorexton MWT result is 20-29 min or leaves room for improvement on tolerability—but also thinks the downside to ALKS is limited and worth owning as ALKS could surprise to the upside.
0 · Reply
Quantumup
Quantumup Oct. 1 at 3:06 PM
Wells Fargo added $ALKS (Overweight) and $CNTA (Overweight) onto its 4Q25 Tactical Ideas List. $AXSM $TAK Wells Fargo said that it sees upside to CNTA shares if ALKS' alixorexton MWT result is 20-29 min or leaves room for improvement on tolerability—but also thinks the downside to ALKS is limited and worth owning as ALKS could surprise to the upside.
0 · Reply
clan
clan Sep. 30 at 6:46 PM
$MNKD $GSK $NOV $TAK $MRK This re-manufactured Clofazimine in inhalation form(s) is going to be HUGE for MannKind! Oct. 2025 publication in the Journal Of Pharmaceutical Sciences -- link --> Pulmonary drug delivery of clofazimine: A route of administration and pharmacokinetics guided repositioning strategy against drug resistant tuberculosis informed by use for other disease indications - ScienceDirect https://share.google/PQ72yMfXnstl0IBax
0 · Reply
clan
clan Sep. 29 at 5:36 PM
$MNKD CLOFAZIMINE (CIS) by Mannkind --------------------------------------------------- Designations: - Phase 3 ICoN-1 international trials • U.S.A. & Japan & Australia & Korea - Fast Tracked by FDA - Orpan Drug - Qualified Infectious Disease Product - Well tolerated - No significant Adverse Events - Localized treatment (lungs) - Improved patient adherence - Indications for arthritis & CANCERs - Current global mkt $2.3B [2023] {even with the adverse events (AEs) caused by other pharmas' current formulations} ...and coming soon..... - - - Clofazimine DPI Partner with $GSK ? $NOV ? $TAK ? Maybe $MRK ?
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 9:05 AM
$TAK Excellent article that nails exactly where TAK stands right now. So if you want to update your TAK knowledge or get acquainted with TAK, this is a must read. https://beyondspx.com/quote/TAK/analysis/takeda-s-pipeline-powerhouse-orexin-and-tyk2-drive-future-growth-amidst-market-shifts-nyse-tak
0 · Reply
TobySmith1366
TobySmith1366 Sep. 23 at 4:55 PM
$TAK “Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan” more to come 🔥🔥🚀
0 · Reply
TobySmith1366
TobySmith1366 Sep. 23 at 4:30 PM
$TAK Keep an eye on NOVAVAX I have a feeling something massive is in the works with Takeda Pharmaceutical and Novavax (NVAX) 🔥🔥🚀
0 · Reply
DocPharm
DocPharm Sep. 10 at 10:21 PM
$ABUS likely for one of Genevant’s partners They have a ton of codeveloped products - it sounds like at least one is showing promise $NVO $BNTX $EDIT $TAK come to mind firstly
1 · Reply
biotech
biotech Sep. 8 at 4:31 PM
0 · Reply